ORMD-0801 (oral insulin): Initiate studies in HbA1c and NASH.
ORMD-0901 (oral GLP-1 analog): File IND followed by Phase 1 pharmacokinetic study and initiation of Phase 2.
Initiate Leptin study and continue to work with Chinese partner HTIT as it prepares to market ORMD-0801 in China.
Continue Big Pharma collaboration.
Subscribe for full text news in your inbox